BLRX BioLineRx Ltd.
Stock Price & Overview

$3.98-0.03 (-0.75%)4:00 PM 07/31/25
NASDAQ | $USD | Post-Market: $3.82 -0.16 (-4.02%) 6:50 PM

BLRX Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

BLRX Analysis

See All Analysis »

BLRX News

See All News »

Latest Headlines

Seasonality

Displays mean and median monthly returns for BLRX in order to identify seasonal patterns.
YearJanFebMarAprMayJunJulAugSepOctNovDec

Ratings Summary

People Also Follow

Similar to BLRX

ETFs Holding BLRX

BLRX Company Profile

BioLineRx Ltd. logo
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector
Health Care
Industry
Biotechnology
Employees
28
Founded
2003
Address
  • Modi’in Technology Park
  • 2 HaMa’ayan Street
  • Hevel Modi'in, 7177871
  • Israel
Phone Number
972 8 642 9100
Website
www.biolinerx.com
Hide

BLRX Revenue

More On Revenue »

BLRX Earnings Per Share

More On Earnings »

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

Dividends

BLRX does not currently pay a dividend.

BLRX Ownership

BLRX Peers

Risk

Technicals

BLRX Transcripts

Investor Presentations

BLRX SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

BLRX Income Statement

BLRX Balance Sheet

BLRX Cash Flow Statement

BLRX Long Term Solvency

BioLineRx Ltd. (BLRX) Frequently Asked Questions